Skip to main content
. 2013 Oct 9;33(41):16323–16333. doi: 10.1523/JNEUROSCI.1971-13.2013

Figure 8.

Figure 8.

Presynaptic inhibition differentially affects UVR and MVR synapses. A, Overlaid averaged evoked responses showing potency for a sample UVR (top) and MVR (bottom) synapse. B, Diary plots for the same synapses shown in A. Baclofen increased the failure rate at both synapses but decreased eEPSC amplitude only at the MVR synapse. C, Summary data showing increased failure rate in the presence of baclofen for UVR (top; control vs baclofen: E1: 0.68 ± 0.062 vs 0.85 ± 0.058, p = 0.0313; E2: 0.37 ± 0.073 vs 0.61 ± 0.104, p = 0.0313; E3: 0.36 ± 0.057 vs 0.53 ± 0.101, p > 0.05; n = 6) and MVR synapses (bottom; control vs baclofen: E1: 0.74 ± 0.058 vs 0.96 ± 0.019; E2: 0.38 ± 0.079 vs 0.86 ± 0.050; E3: 0.26 ± 0.046 vs 0.65 ± 0.070; n = 6, p = 0.0313 for each). CGP (5 μm) reversed failure rate to near control levels for both UVR (E1: 0.70 ± 0.054; E2: 0.40 ± 0.094; E3: 0.27 ± 0.077; n = 5, p > 0.05) and MVR synapses (E1: 0.80 ± 0.094; E2: 0.56 ± 0.113; E3: 0.44 ± 0.111; n = 6, p > 0.05). D, Top, Baclofen and CGP did not alter potency at UVR synapses (ctrl vs bac vs cgp: E1: 1 vs 1.00 ± 0.115 vs 1.14 ± 0.111; E2: 1.07 ± 0.018 vs 1.04 ± 0.082 vs 1.10 ± 0.097; E3: 1.06 ± 0.022 vs 1.05 ± 0.046 vs 1.12 ± 0.076; n = 6,6,5, p > 0.05). Bottom, Baclofen reduced potency at MVR synapses to apparent UVR levels, with only a partial reversal by CGP (ctrl vs bac vs cgp: E1: 1 vs 0.88 ± 0.221 vs 0.85 ± 0.018, n = 6,4,4, p = 0.0364; E2: 1.54 ± 0.092 vs 0.97 ± 0.102 vs 1.07 ± 0.019, n = 6, p = 0.0031; E3: 1.63 ± 0.124 vs 1.01 ± 0.169 vs 1.14 ± 0.084, n = 6, p = 0.0133).